ABL1 and acute lymphoblastic leukemia: The 2023 ICC of Eosinophilic Disorders offers updated and more precise guidance for distinguishing MLN-eo-TK (especially those presenting as ALL) from BCR::ABL1-like B-ALL and de novo T-ALL [3].